glp 1 approved for nash Mechanisms of antidiabetic therapies nonalcoholic steatohepatitis Indications for GLP-1/GIP RA Summary

Predictors of incident heart failure in a large insured population: a one million person-year follow- up study

If you experience significant side effects during this phase, stay at the current dose for an additional week before increasing

Reconstitution should be performed using sterile, high-purity solvents under aseptic laboratory conditions

(May 2006)

Standard qualification criteria include: BMI 30 kg/m (obesity) regardless of comorbidities BMI 27 kg/m (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease Age 18 years or older (Wegovy and Saxenda are also approved for adolescents aged 12 and above